iRECIST: A clarification of tumour response assessment in the immunotherapy era

The advent of immuno-oncology (IO) drugs profoundly changes our understanding of cancer biology as well as the management of patients at bedside. This is especially true for melanoma, renal cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, Hodgkin's lymphoma or bladder cancer, for which these drugs already demonstrated substantial improvements in the patients' outcome. Beyond these indications, objective tumour responses have been reported in more than 20 different cancer types in early phase trials.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nCduBJ
via IFTTT